Published in Clin Cancer Res on December 01, 2004
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer (2010) 1.48
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer (2005) 1.45
Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer (2009) 1.28
miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer (2013) 1.05
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) (2009) 1.03
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha. J Gastroenterol (2006) 0.90
Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer (2010) 0.90
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer (2009) 0.87
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol (2010) 0.86
The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One (2011) 0.84
Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PLoS One (2012) 0.82
Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol (2005) 0.82
Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. Br J Cancer (2007) 0.81
Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med (2012) 0.81
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. Int J Clin Oncol (2007) 0.81
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol (2012) 0.81
Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer. Trends Mol Med (2015) 0.80
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Sci Rep (2017) 0.78
miR-615-3p expression level in bone marrow is associated with tumor recurrence in hepatocellular carcinoma. Mol Clin Oncol (2015) 0.75
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials (2015) 0.75
Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. Hepat Med (2011) 0.75
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell (2011) 4.02
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest (2010) 3.60
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem (2003) 3.41
Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res (2010) 3.40
Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2009) 3.39
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol (2005) 3.23
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
A Bayesian missing value estimation method for gene expression profile data. Bioinformatics (2003) 3.19
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J (2003) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J (2014) 2.76
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem (2005) 2.71
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem (2003) 2.66
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res (2005) 2.53
Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology (2010) 2.48
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol (2013) 2.45
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest (2011) 2.40
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 2.27
OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med (2003) 2.26
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 2.21
A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J (2013) 2.19
Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res (2007) 2.19
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol (2011) 2.18
Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg (2013) 2.17
Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol (2003) 2.16
A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol (2006) 2.16
Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial. Lancet (2013) 2.14
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A (2009) 2.11
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res (2011) 2.11
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol (2004) 2.10
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08
High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg (2005) 2.04
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J (2015) 2.03
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol (2007) 2.02
Laparoscopy-assisted hybrid left-side donor hepatectomy. World J Surg (2013) 2.02
The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun (2011) 2.02
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol (2010) 2.00
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci (2009) 1.95
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology (2013) 1.94
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med (2007) 1.93
Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity (2004) 1.93
Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol (2010) 1.91
Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun (2003) 1.91
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem (2003) 1.86
A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation. J Surg Oncol (2009) 1.85
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med (2003) 1.85
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer (2006) 1.82
Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78
Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol (2004) 1.78